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1.  Introduction
HangAmDan-B (HAD-B) is an upgraded version of 
HangAmDan (HAD) which has been used for solid 
tumors such as pancreatic, lung, colorectal, and 
stomach cancers [1−6] at the East West Cancer 
Center (EWCC), Dunsan Oriental Hospital, Daejeon, 
South Korea, since its development in 1996.
Abstract
The aim of the study was to define the toxicity of HangAmDan-B (HAD-B) in mice 
over the short and long term. HAD-B was studied in 1-week single and 5-week 
repeated oral dose toxicity tests on male Imprinting Control Region mice. Doses 
used in 1 week single oral dose toxicity tests were 0, 0.2, 1, 5, and 25 g/kg/day and 
those of repeated toxicity test were 0, 0.04, 0.2, 1, and 2 g/kg/day. Blood and urine 
samples were assayed and their morphology observed. Numerical data were com-
pared using Mann-Whitney U test and analysis of variance. Significantly decreased 
red blood cell levels in mice from S2-HAD-B, S3-HAD-B, S4-HAD-B, and S5-HAD-B 
groups were observed in single oral dose toxicity tests. Hemoglobin, hematocrit, 
and mean cell hemoglobin values in mice from the S4-HAD-B and S5-HAD-B groups 
were also significantly decreased. No mortalities or significant differences in all 
factors were observed during the dosing period of the repeated dose toxicity test. 
Administering 2 g/kg/day of HAD-B in mice over a 5-week period showed no sig-
nificant hematological changes. However, risk of anemia with more than 5 g/kg/
day administration of HAD-B was found. In general, HAD-B appears to be safe and 
nontoxic, and a no observed adverse effect level in mice was established at 2 g/kg/
day. This data serves as satisfactory preclinical evidence for the safety of HAD-B 
should a future clinical trial for HAD-B be launched. Further studies are required to 
confirm these safety results and to carry out a safety trial in humans.
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HAD comes from “Xi Huang Wan,” a formula for 
solid masses, mentioned in the classical text Wai Ke 
Zheng Zhi Quan Sheng Ji (by Pan Wei, 1883). From 
the original ingredients of Xi Huang Wan, modifica-
tions have been made through multi ple screening 
of herbs and research. As a result, HAD was devel-
oped consisting of Coicis semen, Panax notogin-
seng Radix, Hippocampus, Cordyceps militaris, 
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Cremastrae appendiculata Tuber, Panax ginseng 
Radix, Bovis calculus, Margarita, and Moschus. 
Several research findings have supported the effi-
cacy of HAD in immune function, anti-angiogenesis, 
and inhibition of cancer cell proliferation and me-
tastasis [7−9]. Case reports have even been selected 
as part of the National Cancer Institute’s Best Case 
Series Program using HAD [10]. However, complica-
tions with future utilization of HAD have appeared. 
Hippocampus was selected as one of the Conven-
tion on International Trade in Endangered Species’ 
endangered animals [11] and the high quantity of 
Coicis semen required for the formula, with its rel-
atively low anti-cancer effect and high starch con-
tent, was seen inappropriate for long term usages. 
To overcome these difficulties HAD-B has been newly 
formulated by removing Coicis semen, Hippocampus, 
and Moschus and by adding Boswellia carteri and 
Commiphora myrrha. According to Oriental medi-
cine, Boswellia carteri and Commiphora myrrha 
have the ability to eliminate pathological masses, 
promote blood circulation, remove blood stasis, and 
control pain. After the modification, HAD-B has shown 
better efficacy in inhibiting migration and prolifer-
ation of human umbilical vein endothelial cells and 
restraining formation of capillary tube structures 
when compared with HAD [12]. Nonetheless, study 
and evaluation on safety of HAD-B remains minimal 
because of its recent development.
The necessity of defining the safety of HAD-B 
for clinical use has increased and is inevitable for 
future, broader application of HAD-B in oriental 
medicine cancer therapy. In this study, toxicity of 
HAD-B as a whole formula is investigated rather 
than individual herbal ingredients; given that in 
clinical settings, use of multiple herbs as a prescrip-
tion is far more common, although the exact chem-
ical interactions of each herb are as yet unknown.
Systemic clinical toxicity studies of the formula 
have not been performed due to the limitations of 
conducting a human clinical trial using a prescrip-
tion without any evidence of safety. Therefore, 
preliminary studies to evaluate the safety of HAD-B 
in 1-week single and 5-week repeated oral dose 
toxicity tests to build safety evidence for future 
clinical trials are conducted in these investigations.
2. Materials and Methods
2.1. Test materials
HAD-B is an herbal formula consisting of eight 
herbal ingredients in a powder form (Table 1). The 
crude ground herbs of HAD-B were obtained from 
Dunsan Oriental Hospital (Daejeon, Korea), and 
stored at −20ºC until use.
Table 1 Ingredients of HangAmDan-B
Herbs (Latin botanical name) Relative amount (mg)









Total amount (1 capsule) 499.8
2.2. Animals
Fifty male Imprinting Control Region (ICR) mice 
(30−32 g, 5-week old upon receipt, Samtako, 
Korea) were used after 8 days of acclimatization. 
Animals were housed individually in suspended 
wire cages (500 mm × 300 mm × 200 mm) in a tem-
perature (20−25ºC) and humidity (40−45%) control-
led room. Light/dark cycle was 12/12 hours and 
feed (Pellet, Samyang, Korea) and water were sup-
plied free to access during the study.
2.3. Toxicity study
No observed adverse effect level was sought for 
mice. Fifty male ICR mice were equally distributed 
into 10 groups (5 per each of the 5 groups for sin-
gle dose toxicity testing, 5 per each of the 5 groups 
for repeated dose toxicity testing). Based on the 
use of HAD-B in animal studies and clinical applica-
tions, dosing levels of 0, 0.2, 1, 5 and 25 g/kg/day 
for single dose and 0, 0.04, 0.2, 1 and 2 g/kg/day 
for repeated dose toxicity tests were selected.
Representative dose preparations for each level 
were analyzed for homogeneity of distribution, 
concentration, and stability during the study. An 
appropriate amount of the test or vehicle control 
substance was administered orally to each mouse 
for 1 week in the single dose toxicity test and for 
5 weeks in the repeated dose toxicity test. The 
5-week period for longer term repeated dose toxic-
ity test was selected based on EWCC’s standard hos-
pitalization period of 3 weeks, giving 2 weeks before 
and after the treatment time. Mice were observed 
for mortality, signs of gross toxicity, and behavioral 
changes at least once a day during the study.
Body weights were recorded during the acclima-
tion period and weekly during the exposure period. 
Ophthalmological examination was conducted by 
observing the manifestation of both eyes on the last 
week of the experiment. Blood was collected from 
all mice at the end of the study prior to sacrifice. 
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Blood samples were evaluated for clinical pathology 
findings.
2.3.1.  Single oral dose toxicity test
Single oral dose toxicity testing was conducted on 
five groups of mice (0 g/kg, S1-HAD-B; 0.2 g/kg, 
S2-HAD-B; 1 g/kg, S3-HAD-B; 5 g/kg, S4-HAD-B; 
25 g/kg, S5-HAD-B) for 1 week. While the extract was 
delivered via oral Zonde needle f 0.9 × 50 mm 
(Natsume Seisakusho Co., Ltd., Tokyo, Japan) to test 
groups, distilled water was administered to the con-
trol group. Total volume administered was 8.8 μL.
2.3.2.  Repeated oral dose toxicity test
Repeated oral dose toxicity testing was conducted on 
five groups of mice (0 mg/kg, R1-HAD-B; 0.04 g/kg, 
R2-HAD-B; 0.2 g/kg, R3-HAD-B; 1 g/kg, R4-HAD-B; 
2 g/kg, R5-HAD-B) for 5 weeks. While the extract 
was delivered via oral Zonde needle f 0.9 × 50 mm 
(Natsume Seisakusho Co., Ltd., Tokyo, Japan) to test 
groups, distilled water was administered to the con-
trol group. Total volume administered was 8.8 μL.
2.4.  Hematology, biochemical parameters 
and urine analysis
All mice were fasted approximately 18 hours prior 
to each blood draw. Blood samples were collected 
from the descending aorta under ether anesthesia 
at the end of the experiment. Urine analysis for 
specific gravity, pH, leukocyte, nitrite, protein, glu-
cose, ketone, urobilinogen, bilirubin, and blood was 
conducted using Bayer Diagnostics Multistix 10SG 
reagent strips (Bayer Inc., Pittsburgh, PA, USA) and 
urine chemistry analyzer Clinitek 500 (Siemens Inc., 
DC, USA).
2.5.  Morphologic pathology evaluation
In repeated toxicity testing, complete morphologic 
evaluations were performed immediately following 
the death of the animals to avoid autolysis of the or-
gans. Fasted surviving animals were weighed before 
sacrifice at the end of the trial using anesthetic ether.
Gross pathologic evaluations were performed 
and weights of the liver, kidney, heart, spleen, lung, 
testis, and brain were measured and recorded im-
mediately afterwards. Relative organ weight (organ 
to body weight ratio) were also calculated and 
recorded.
2.6.  Statistical analysis
Mann-Whitney U test was used to compare the ho-
mogeneity of variance in numerical data. One way 
analysis of variance was conducted when homo-
geneity of variance in data between groups was 
present. For all analyses, SPSS version 10.1 (SPSS 
Inc., Chicago, IL, USA) was used and a p value of less 
than 0.05 was considered statistically significant.
3.  Results
3.1.  S2-, S3-, S4- and S5-HAD-B groups 
showed abnormal hematologic values
Comparatively lower red blood cell (RBC) levels 
were seen in S2-HAD-B (8.5 M/μL), S3-HAD-B 
(8.7 M/μL), S4-HAD-B (8.5 M/μL), and S5-HAD-B 
(8.3 M/μL), which were statistically significant 
from control. Hemoglobin (Hb) levels in S2-HAD-B 
(11.8 g/dL) and S3-HAD-B (12.0 g/dL) were higher 
than that of S1-HAD-B and significantly higher than 
that of S4-HAD-B (8.7 g/dL) and S5-HAD-B (8.3 g/
dL). Hematocrit (HCT) levels in S2-HAD-B (39.0%), 
S4-HAD-B (37.3%), and S5-HAD-B (37.4%) were sig-
nificantly lower than that of S1-HAD-B. Mean cell 
hemoglobin (MCH) was higher in S2-HAD-B (14.0 pg) 
and S3-HAD-B (13.7 pg) than that of S1-HAD-B. In 
contrast, MCH levels of S4-HAD-B (10.3 pg) and S5-
HAD-B (9.9 pg) were lower than that of S1-HAD-B 
(Table 2).
3.2.  S2-, S3-, S4-, and S5-HAD-B groups 
showed abnormal values of total 
protein, albumin, BUN, creatinine 
and triglycerides
Lower levels of total protein were shown in S2v-
HAD-B (4.7 g/dL), S3-HAD-B (4.7 g/dL), S4-HAD-B 
(4.7 g/dL), and S5-HAD-B (4.7 g/dL). The A/G ratio 
levels of S3-HAD-B (1.1) and S5-HAD-B (1.1) were 
statistically significant. Creatinine levels of S2-
HAD-B (0.1 mg/dL), S3-HAD-B (0.1 mg/dL), S4-HAD-B 
(0.1 mg/dL), and S5-HAD-B (0.2 mg/dL) were all 
lower than that of S1-HAD-B. BUN levels of S2-
HAD-B (26.9 mg/dL) and S5-HAD-B (25.8 mg/dL) were 
also lower than that of S1-HAD-B. Triglyceride levels 
of S2-HAD-B (190.6 mg/dL), S3-HAD-B (245.8 mg/dL), 
S4-HAD-B (168.2 mg/dL), and S5-HAD-B (163.8 mg/dL) 
were also significantly lower than that of S1-HAD-B 
(Table 3).
3.3.  R2-HAD-B mice show significant 
increase in body weight
Average body weight of the treated mice was com-
parable to that of the control group regardless of 
dosage level. Notably, we observed significantly 
higher body weight in the R2-HAD-B group at week 
4 compared with the control group (Figure 1).
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Table 3   Urinalysis of mice treated with HangAmDan-B (HAD-B), 1-week oral administration
Group/dose Total protein Albumin A/G Creatinine BUN Total cholesterol Triglycerides GOT GPT
(g/kg/day) (g/dL) (g/dL) ratio (mg/dL) (mg/dL) (mg/dL) (mg/dL) (U/L) (U/L)
S1-HAD-B (0)
 Mean 5.1 2.5 1.0 0.3 33.8 90.8 326.6 73.8 48.8
 SD 0.10 0.05 0.02 0.02 1.43 4.45 23.08 9.97 12.08 
 No. 5 5 5 5 5 5 5 5 5
S2-HAD-B (0.2)
 Mean 4.7* 2.4* 1.0 0.1* 26.9* 88.2 190.6* 71.0 35.2
 SD 0.04 0.04 0.02 0.00 0.90 3.80 9.18 10.56 1.47 
 No. 5 5 5 5 5 5 5 5 5
S3-HAD-B (1)
 Mean 4.7* 2.2 1.1* 0.1* 32.2 80.6 245.8* 131.6* 56.8
 SD 0.12 0.07 0.02 0.02 2.69 4.34 20.72 25.93 20.73 
 No. 5 5 5 5 5 5 5 5 5
S4-HAD-B (5)
 Mean 4.7* 2.4 1.1 0.1* 33.3 84.4 168.2* 75.8 38.6
 SD 0.04 0.08 0.08 0.02 1.35 3.51 10.61 4.57 5.25 
 No. 5 5 5 5 5 5 5 5 5
S5-HAD-B (25)
 Mean 4.7* 2.5 1.1* 0.2* 25.8* 90.2 163.8* 66.0 33.8
 SD 0.04 0.03 0.02 0.05 1.43 3.80 16.68 4.95 3.01 
 No. 5 5 5 5 5 5 5 5 5
*p < 0.05. A/G = albumin/globulin; BUN = blood urea nitrogen; GOT = glutamic-oxaloacetic transaminase; GPT = glutamic-pyruvic 
transaminase.
Table 2 Hematologic values of mice treated with HangAmDan-B (HAD-B) with 1-week oral administration
Group/dose WBC RBC Hb HCT MCV MCH MCHC PLT
(g/kg/day) (K/μL) (M/μL) (g/dL) (%) (fL) (pg) (g/dL) (K/μL)
S1-HAD-B (0)
 Mean 1.0 9.9 10.4 44.5 45.0 10.6 23.5 820.0 
 SD 0.17 0.48 0.47 2.12 0.23 0.08 0.11 81.39 
 No. 5 5 5 5 5 5 5 5
S2-HAD-B (0.2)
 Mean 0.8 8.5* 11.8* 39.0* 46.0 14.0* 30.3* 848.2 
 SD 0.13 0.24 0.34 0.98 0.56 0.35 0.47 40.82 
 No. 5 5 5 5 5 5 5 5
S3-HAD-B (1)
 Mean 1.3 8.7* 12.0* 39.9 45.8 13.7* 30.0* 863.0 
 SD 0.28 0.26 0.27 1.20 0.56 0.19 0.48 19.05 
 No. 5 5 5 5 5 5 5 5
S4-HAD-B (5)
 Mean 1.2 8.5* 8.7* 37.3* 44.0* 10.3* 23.4 995.4 
 SD 0.23 0.21 0.23 0.90 0.33 0.09 0.33 47.00 
 No. 5 5 5 5 5 5 5 5
S5-HAD-B (25)
 Mean 1.1 8.3* 8.3* 37.4* 44.9 9.9* 22.2* 942.0 
 SD 0.07 0.15 0.18 0.98 0.51 0.17 0.44 20.21 
 No. 5 5 5 5 5 5 5 5
*p < 0.05. WBC = white blood cells; RBC = red blood cells; Hb = hemoglobin; HCT = hematocrit; MCV = mean corpuscular volume; 
MCH = mean cell hemoglobin; MCHC = mean corpuscular hemoglobin concentrations; PLT = platelet.
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Table 4 Hematologic values of mice treated with HangAmDan-B (HAD-B), 5-week oral administration
Group/dose WBC RBC Hb HCT MCV MCH MCHC PLT
(g/kg/day) (K/μL) (M/μL) (g/dL) (%) (fL) (pg) (g/dL) (K/μL)
R1-HAD-B (0)
 Mean 1.5 8.6 11.0 35.6 41.3 12.7 30.8 823.0 
 SD 0.19 0.09 0.24 0.45 0.25 0.14 0.40 22.91 
 No. 5 5 5 5 5 5 5 5
R2-HAD-B (0.04)
 Mean 1.6 8.6 10.8 36.7 42.8* 12.6 29.5* 844.6 
 SD 0.28 0.13 0.14 0.41 0.46 0.19 0.23 30.85 
 No. 5 5 5 5 5 5 5 5
R3-HAD-B (0.2)
 Mean 1.5 8.6 11.0 37.0 43.0* 12.8 29.8 814.4 
 SD 0.29 0.18 0.07 0.88 0.50 0.22 0.60 31.98 
 No. 5 5 5 5 5 5 5 5
R4-HAD-B (1)
 Mean 1.9 8.8 10.9 36.8 41.7 12.4 29.7* 871.2 
 SD 0.54 0.18 0.15 0.69 0.21 0.13 0.32 26.32 
 No. 5 5 5 5 5 5 5 5
R5-HAD-B (2)
 Mean 1.7 8.8 10.9 36.2 41.1 12.4 30.0 859.0 
 SD 0.33 0.17 0.36 0.82 0.42 0.20 0.42 16.47 
 No. 5 5 5 5 5 5 5 5
*p < 0.05. WBC = white blood cells; RBC = red blood cells; Hb = hemoglobin; HCT = hematocrit; MCV = mean corpuscular volume; 






















Figure 1 Body weight changes of mice in 5-week 
repeated oral dose toxicity test for HangAmDan-B (HAD-
B). Average body weight of R2-HAD-B group mice was 
significantly increased after 4 weeks of administration 
of HAD-B (0 g/kg, S1-HAD-B; 0.2 g/kg, S2-HAD-B; 1 g/kg, 
S3-HAD-B; 5 g/kg, S4-HAD-B; 25 g/kg, S5-HAD-B).
3.4.  R2-, R3-, and R4-HAD-B groups showed 
MCV and MCHC
The abnormal mean corpuscular volumes (MCV) of 
R2-HAD-B (42.8 fL) and R3-HAD-B (43.0 fL) were 
higher than that of R1-HAD-B. Mean corpuscular 
hemoglobin concentrations (MCHC) of R2-HAD-B 
(29.5 g/dL) and R4-HAD-B (29.7 g/dL) were also 
lower than that of R1-HAD-B (Table 4).
3.5.  R2- and R4-HAD-B groups have 
abnormal creatinine, BUN and 
A/G ratio values
The creatinine level of R2-HAD-B (1.1) was signifi-
cantly lower than that of R1-HAD-B. The blood 
urea nitrogen (BUN) level of R2-HAD-B (25.7 mg/dL) 
was lower than that of R1-HAD-B. The albumin/
globulin (A/G) ratio of R4-HAD-B (1.1) was signifi-
cantly higher than that of R1-HAD-B (Table 5).
4.  Discussion
This study was performed to determine the toxic-
ity of HAD-B in short term and long term settings. 
Boswellia carteri and Commiphora myrrha are two 
new herbs that have been added to the previously 
used anti-cancer formula HAD of the EWCC, Korea. 
Both herbs are known to have actions to remove 
pathological masses and blood stasis, promote blood 
circulation, control pain, and inhibit angiogenesis. 
However, studies and evaluation on safety of HAD-B 
are minimal due to its recent development.
Although studies on toxicity of HAD-B are lim-
ited, there are studies reporting toxicities of the 
single herbs used in HAD-B. The LD50 for ginseng 
ranges from 10 to 30 g/kg, with a lethal oral dose 
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Table 5 Urinalysis of mice treated with HangAmDan-B (HAD-B), 5-week oral administration
Group/dose Total Albumin A/G Creatinine BUN Total cholesterol Triglycerides GOT GPT
(g/kg/day) protein (g/dL) (g/dL) ratio (mg/dL) (mg/dL) (mg/dL) (mg/dL) (U/L) (U/L)
R1-HAD-B (0)
 Mean 4.8  2.4  1.0  0.2  32.2  74.6  279.8  66.2  33.4
 SD 0.15  0.09  0.03  0.04  2.36  7.17  53.85  8.28  5.84
 No. 5 5 5 5 5 5 5 5 5
R2-HAD-B
(0.04)
 Mean 4.6  2.3  1.0  0.1* 25.7*  74.4  183.8  80.8  63.4 
 SD 0.04  0.04  0.04  0.00  0.94  3.83  20.38  25.06  36.81 
 No. 5 5 5 5 5 5 5 5 5
R3-HAD-B
(0.2)
 Mean 4.6 2.2  1.1  0.2  32.1  71.0  212.0  122.4  66.0 
 SD 0.09 0.05  0.05  0.04  1.60  2.12  11.00  29.56  18.88 
 No. 5 5 5 5 5 5 5 5 5
R4-HAD-B (1)
 Mean 4.7 2.5  1.1* 0.2  32.5  71.8  234.4  67.8  40.4 
 SD 0.14 0.11  0.05  0.03  1.29  5.24  13.29  7.74  4.67 
 No. 5 5 5 5 5 5 5 5 5
R5-HAD-B (2)
 Mean 5.0 2.6  1.1  0.2  34.4  75.2  264.2  70.0  30.6 
 SD 0.07 0.04  0.03  0.03  1.51  2.13  33.61  9.33  2.56 
 No. 5 5 5 5 5 5 5 5 5
*p < 0.05. A/G = albumin/globulin; BUN = blood urea nitrogen; GOT = glutamic-oxaloacetic transaminase; GPT = glutamic-pyruvic 
transaminase.
set as high as 5 g/kg in mice [13]. In humans, 100 mL 
of 3% ginseng extract intake will cause light anxi-
ety and 200 mL of 3% ginseng extract intake will 
bring on itchiness and headache [14]. According to 
a study, suggested clinical dosage of ginseng is 2.0 
to 10 g/day with adverse effects of hypertension, 
gastrointestinal disturbances, insomnia, and ner-
vousness when taken beyond the safe dosage [15]. 
Another study suggests clinical dosage of Cremastae 
appendicular Tuber to be 3−10 g/day, and mentions 
adverse effects of gastrointestinal disorder such as 
nausea and vomiting [16].
HAD-B was tested in 1-week single and 5-week 
repeated oral dose toxicity tests on male ICR mice. 
In single oral dose toxicity tests, no mortalities, no 
ophthalmologic findings, and no abnormal clinical 
signs were observed. There were no significant dif-
ferences in average body and organ weights be-
tween control and treated groups regardless of 
dosage level. However, in hematological analysis, 
significantly lower RBC values in mice of the 
S2-HAD-B, S3-HAD-B, S4-HAD-B, S5-HAD-B were ob-
served. Hb, HCT, and MCH values in mice of the S4-
HAD-B and S5-HAD-B groups were also significantly 
low. Lower levels of RBC, Hb, HCT and MCH indicate 
blood loss, which may be caused by gastroin testinal 
bleeding, bleeding in internal organs, and hemo-
lytic anemia. In this case, hemolytic anemia was 
ruled out as urinalysis results revealed no presence 
of free hemoglobin in urine samples. More tests are 
needed for differential diagnosis such as occult blood 
test for gastrointestinal bleeding and autopsy to de-
termine whether the internal bleeding was present 
or not. Special attention is recommended when 
administering HAD-B to patients with gastric ulcer 
or anemia, considering the possible risk of blood 
loss with more than 5 g/kg/day of HAD-B intake.
Overall values of biochemical parameters indi-
cated that treated mice were comparable to con-
trols regardless of dosage level. However, S2-HAD-B, 
S3-HAD-B, S4-HAD-B, and S5-HAD-B groups showed 
significant decrease in creatinine and triglyceride 
levels. Creatinine level decrease when body muscle 
mass is reduced. However, all mice gained body 
weight; thus, the decreased creatinine level could 
not be explained in terms of weight changes. 
Triglycerides can induce atherosclerosis when in-
creased. Decreased triglycerides indicate an im-
proved metabolic condition in the body. No 
significant differences between the control group 
and treatment groups were found during the dos-
ing period in urinalysis assessment.
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In repeated dose toxicity testing, there were no 
mortalities, no ophthalmologic findings, and no 
abnormal clinical observations made. Average over-
all body weight data indicated that the treated 
mice were comparable to the controls regardless 
of dosage level. Hematological analysis showed no 
differences in most parameters examined. The av-
erage overall values for biochemical parameters 
indicated that the treated mice were comparable 
to controls regardless of dosage level. There were 
no significant differences in urine analysis during 
the dosing period between all groups.
Administering 2 g/kg/day of HAD-B in mice over 
a 5-week period showed no significant hematologi-
cal changes. However, risk of anemia with more 
than 5 g/kg/day of HAD-B administration was found. 
In general, HAD-B appeared to be safe and non-toxic 
according to the findings, and a no observed ad-
verse effect level in mice was established at 2 g/
kg/day. This data serves as satisfactory preclinical 
evidence of safety to allow the launch of future 
clinical trials for HAD-B. More studies are required 
to confirm these safety results and to further carry 
out a safety trial in humans.
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